Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23539369 | 0.97 | CRBN (0.50) | CRBNDDB1HDAC2HDAC1SOS1 | |
| SCHEMBL23538715 | 0.86 | DDB1 (0.55) | CRBNDDB1 | |
| SCHEMBL23538259 | 0.84 | DDB1 (0.43) | CRBNDDB1 | |
| SCHEMBL29535442 | 0.84 | DDB1 (0.43) | CRBNDDB1 | |
| SCHEMBL23538393 | 0.83 | DDB1 (0.53) | CRBNDDB1SOS1 | |
| SCHEMBL29977165 | 0.83 | DDB1 (0.53) | CRBNDDB1SOS1 | |
| SCHEMBL23539064 | 0.81 | DDB1 (0.52) | CRBNDDB1HDAC2HDAC1 | |
| SCHEMBL30990634 | 0.80 | DDB1 (0.50) | CRBNDDB1 | |
| SCHEMBL29977269 | 0.79 | CRBN (0.52) | CRBNDDB1 | |
| SCHEMBL24125425 | 0.78 | DDB1 (0.56) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347044-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022251539-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-4076450-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |